MAIA Biotechnology: Progress In The THIO-101 Trial Sets Up A 2023 Catalyst (NYSE:MAIA)

Minerva Studio/iStock through Getty Pictures

MAIA Biotechnology (NYSE:MAIA) is growing 6-thio-2′-deoxyguanosine (6-thio-dG), a telomere focusing on agent, for quite a lot of cancers. A current replace on the corporate’s scientific trial and fundraising by the corporate are positives which have made the identify value writing

THIO-101 MAIA trial design

Determine 1: Schematic of THIO-101 trial of 6-thio-dG (or just THIO). ORR refers to general response price, DCR to illness management price, DoR to period of response. (MAIA Company Presentation, June 2023.)

THIO mechanism of action 6-thio-2'deoxyguanosine or 6-thio-dG

Determine 2: Mechanism of anti-cancer exercise for MAIA’s 6-thio-dG. (MAIA Company Presentation, June 2023.)

Survival data plot thio-101 6-thio-dG

Determine 3: Preliminary survival knowledge from the THIO-101 trial of 6-thio-dG in NSCLC. (MAIA Company Presentation, June 2023.)

Back To Top